NPP1 fusion proteins
AssigneeSynageva BioPharma Corp.
InventorsAnthony Quinn, Alex J. Harvey, Zhinan Xia
Life of this patent
Estimating the term…
Abstract
The present invention provides a novel fusion polypeptide containing a catalytic portion of NPP1 fused to a targeting moiety, nucleic acids encoding the fusion polypeptide, a vector containing the nucleic acid integrated thereinto, a host cell transformed with the vector and pharmaceutical compositions comprising the fusion polypeptide.
Claims19
An isolated NPP1 fusion protein, comprising an NPP1 component, a targeting moiety, and an Fc region of an immunoglobulin, wherein a) the NPP1 component comprises the cysteine-rich region and the C-terminus catalytic domain of NPP1, b) the targeting moiety and the Fc region are each located C-terminally to the NPP1 component, and c) the isolated NPP1 fusion protein has NPP1 enzymatic activity.
Dependencies are inferred from the claim text.